2020-06-23
Camurus raises full year 2020 revenue guidance
The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and Australia.
Read more: https://www.camurus.com
2020-06-23
The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and Australia.
Read more: https://www.camurus.com
2018-12-07
Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…
Read more2018-11-22
Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first…
Read more2018-10-26
AF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash wit…
Read more2018-10-26
“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for lau…
Read more2018-07-20
Sandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product…
Read more